AOD-9604

AOD-9604 is a peptide fragment, a term for a small chain of amino acids. Specifically, it’s a modified piece of the tail end of human growth hormone (hGH), containing the amino acid sequence 177-191. This fragment was isolated because scientists observed that the fat-burning effects of hGH seemed to be located in this specific part of the hormone molecule. The goal of its development was to create a substance that could offer the lipolytic (fat-releasing) benefits of hGH without the other, sometimes unwanted, effects. These other effects include things like muscle growth, changes in insulin sensitivity, or an increase in the hormone IGF-1. By creating this fragment, researchers aimed to build a more targeted tool focused purely on fat metabolism.

The development of AOD-9604—which stands for Anti-Obesity Drug—was undertaken by an Australian biotechnology company. Their research focused on creating a compound that could mimic the natural fat-processing action of hGH. Because it doesn’t contain the full sequence of the growth hormone molecule, it does not bind to the hGH receptor. This is a crucial distinction. It means that AOD-9604 is not simply a smaller version of hGH; it’s a distinct peptide that interacts with the body in a much more specific way. This has made it a subject of interest for people who are focused on body composition and fat loss, but who do not want the broader systemic effects that come with administering full-length growth hormone.

In the research market, AOD-9604 is typically sold as a lyophilized, or freeze-dried, white powder in glass vials. This form keeps the peptide stable for shipping and storage. Common vial sizes include 2mg, 5mg, or sometimes 10mg of the peptide. To be used, this powder must be reconstituted, a process of mixing it with a sterile liquid like bacteriostatic water. The resulting solution is then clear and can be dosed with an insulin syringe. The concentration of the final liquid depends entirely on how much water is added, which is why accurate measurements are so important for consistent tracking, a process this app helps simplify. The 5mg vial is a very common size that researchers and individuals often work with.

The typical dosing cadence for AOD-9604 is often once a day. Many protocols suggest taking it in the morning on an empty stomach to maximize its potential interaction with fat cells when insulin levels are lowest. Users often wait anywhere from 30 minutes to a few hours before eating their first meal. Doses themselves can vary, but a common range people explore is between 250 and 350 micrograms (0.25mg to 0.35mg) per day. Some users may split this into two smaller doses, but a single morning administration is the most frequently discussed protocol. People often run it for a set period, such as a number of weeks or months, followed by a break, to assess its effects on their body composition goals.

The mechanism of AOD-9604 is quite unique and is the primary reason it was developed. Unlike human growth hormone (hGH), AOD-9604 does not work by binding to the official hGH receptor. This means it doesn’t trigger the downstream signaling that leads to the release of IGF-1, muscle cell growth, or potential impacts on insulin sensitivity. Instead, its action is believed to be much more focused. The peptide is thought to directly interact with fat cells to kickstart a process called lipolysis, which is the breakdown of stored fats (triglycerides) into free fatty acids that the body can then use for energy. It essentially encourages fat cells to release their contents.

At the same time it’s stimulating fat release, AOD-9604 is also thought to inhibit lipogenesis—the body’s process of creating and storing new fat. So, it’s believed to work from two sides: helping to burn existing fat while also working to prevent new fat from accumulating. This dual action is what makes it a compelling subject of study for fat loss. One of the proposed pathways for this action is through the beta-3 adrenergic receptors, which are found in high concentrations on fat cells. Activation of these receptors is known to initiate fat breakdown. AOD-9604 is thought to be an agonist of these receptors, effectively flipping the switch that tells fat cells to start breaking down.

This targeted mechanism is what sets AOD-9604 apart. While hGH has powerful fat-loss properties, it also comes with a host of other systemic effects because it influences so many different cell types throughout the body. For individuals whose primary goal is to change body composition by reducing fat mass, the other effects of hGH might be unnecessary or even unwanted. AOD-9604 was engineered to strip away those other functions and isolate just one: the regulation of fat. Early clinical trials explored whether this peptide could produce measurable fat loss in obese individuals without adversely affecting blood sugar levels or causing tissue growth, which the data suggested was the case.

The most common protocol for AOD-9604 involves a single daily administration. Users typically track a dose ranging from 250 mcg to 350 mcg (or 0.25mg to 0.35mg). This dose is almost always taken on an empty stomach, which is considered a critical part of the protocol. The most frequent timing is first thing in the morning, at least 30-60 minutes before the first meal of the day. The rationale behind this timing is to allow the peptide to work in a "fasted state" when insulin levels are low. High levels of insulin, which are present after a meal, can interfere with lipolysis and may blunt the potential effects of the peptide.

After the morning injection, users often continue to fast for a period of time, with some protocols suggesting waiting up to three hours before eating. This is to provide the longest possible window for the released fatty acids to be used by the body for energy. Taking AOD-9604 and then immediately eating a carbohydrate-rich meal would be counterproductive, as the body would likely just use the energy from the food and re-store the fatty acids that the peptide helped release. The effectiveness of the protocol is often seen as being tightly linked to disciplined timing around meals and an overall diet that supports the use of fat for fuel.

In terms of cycling, there is no single established rule, and practices vary. Some users track AOD-9604 continuously for several months, while others prefer a more cyclical approach, such as using it for eight to twelve weeks followed by a break of similar length. Another common strategy is to use it five days a week with a two-day break over the weekend. This "5 on, 2 off" pattern is thought by some to help maintain the body’s sensitivity to the peptide over longer periods. Titration is not always necessary with AOD-9604 as it is generally well-tolerated, but some individuals may start with a lower dose (e.g., 150-200 mcg) for the first week to assess their personal response before moving up to their target dose.

Reconstituting AOD-9604 correctly is the first step toward consistent and accurate tracking. The peptide arrives as a delicate, freeze-dried powder that must be mixed into a liquid solution before it can be measured and administered. The standard liquid for this is bacteriostatic water, which is sterile water that contains a small amount of benzyl alcohol to prevent bacterial growth. When you are ready to mix, you’ll first want to gently tap the vial to make sure all the powder has settled at the bottom. Then, using a fresh syringe, draw up your chosen amount of bacteriostatic water—in our example, we will use 2mL.

With your 2mL of water in the syringe, you will carefully insert the needle through the rubber stopper of the AOD-9604 vial. Angle the needle so the water runs down the inside wall of the vial instead of spraying directly onto the peptide powder. This gentle technique helps prevent any potential damage to the fragile peptide molecules. Once all the water is in, you should gently swirl the vial or roll it between your hands until the powder is fully dissolved. Do not shake the vial vigorously. The final solution should be completely clear. With a 5mg vial and 2mL of water, your final concentration is 2.5mg of AOD-9604 for every 1mL of liquid.

Now, let's look at how to draw a specific dose. If your target dose is 0.3mg, you need to do a little math, which the Peptide Pilot calculator handles for you. With a concentration of 2.5mg/mL, the calculation is: (0.3mg dose / 2.5mg per mL) = 0.12mL of liquid. Since a standard insulin syringe measures volume in units (where 100 units equals 1mL), you would need to draw 12 units on the syringe to get your 0.3mg dose. Being precise in both reconstitution and dose drawing is key to a protocol’s consistency and makes the data you track in the app much more reliable.

Proper storage of AOD-9604 is crucial for maintaining its potency and stability. Before it’s mixed, the lyophilized (freeze-dried) powder is relatively stable. It should be kept away from light and in a cool environment. The best place for it is in a refrigerator, at temperatures between 2°C and 8°C (36°F and 46°F). While it can survive shipping at ambient temperatures for a short period, long-term storage at room temperature is not advised as it can cause the peptide to slowly degrade over time. Never freeze the unmixed powder.

Once you have reconstituted the peptide by mixing it with bacteriostatic water, it becomes much more fragile. The liquid solution MUST be stored in the refrigerator at all times, again between 2°C and 8°C. Do not leave it out on the counter. The shelf life of reconstituted AOD-9604 is a subject of some debate, but it is generally considered to be potent for up to four weeks when properly refrigerated. After this point, the peptide may begin to break down, and its effectiveness could be diminished. To ensure you are using it within its optimal window, it’s good practice to write the date of reconstitution on the vial itself.

The Peptide Pilot app is designed to make tracking your AOD-9604 protocol simple and accurate. When you first get your vial, you’ll start by setting up a new peptide in the app. You’ll enter the total amount of peptide in the vial—for example, 5mg. Next, you’ll enter the amount of diluent (bacteriostatic water) you used for reconstitution, such as 2mL. The app instantly calculates the resulting concentration for you, so you know exactly how many milligrams of AOD-9604 are in every milliliter or unit of your solution. This one-time setup removes the need for manual calculations every time you prepare a dose.

Each day, you’ll log your dose in the app. Let’s say your target is 0.3mg. You can simply enter "0.3mg" as your dose amount. Based on the vial information you entered earlier, the app will automatically tell you how many units that corresponds to on an insulin syringe—in this case, 12 units. This feature helps eliminate the most common source of error: incorrect dose calculation. You just draw up the specified number of units and you can be confident you’re administering the exact amount you intended to. You can also add notes to each entry, such as the time of day or whether you took it in a fasted state, to add more context to your log.

Beyond just logging doses, the app serves as a comprehensive journal for your entire protocol. Since AOD-9604 is used for body composition, you can use the app’s tracking features to monitor relevant metrics. You might log your body weight daily, or take weekly measurements of your waist, hips, or other areas. If you have access to a smart scale or body fat caliper, you can also log your body fat percentage. Over time, you can view this data in graphs alongside your dosing history, giving you a clear visual representation of your journey and helping you assess how your AOD-9604 protocol correlates with the changes you’re observing.